Cytosorbents Corp CTSO
Cytosorbents Corp (Nasdaq: CTSO) is a cardio-renal-metabolic medical device company. Its next catalyst on record is CytoSorbents expects to achieve operating cash flow breakeven in the second half of 2026. (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CytoSorbents expects to achieve operating cash flow breakeven in the second half of 2026. (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DrugSorb-ATR antithrombotic removal system | Perioperative bleeding in CABG on ticagrelor (FDA De Novo denied; new De Novo planned) | — | NA_NON_THERAPEUTIC |
| CytoSorb | Critical care / cardiac surgery blood purification (CE-marked; US EUA for COVID-19 only; not FDA cleared) | — | NA_NON_THERAPEUTIC |
| ECOS-300CY / PerSorb | Ex vivo organ perfusion (CE-marked) | — | NA_NON_THERAPEUTIC |
| VetResQ | Animal blood purification (veterinary) | — | NA_NON_THERAPEUTIC |
Recent results and decisions
- Sep 22, 2026n/a CytoSorbents regained compliance with Nasdaq minimum bid price requirement but remains non-compliant with MVLS requirement with a December 28, 2026 deadline.
On September 22, 2026, the Company received a letter from the Staff confirming that the Company has regained compliance with the Minimum Bid Price Requirement and that the matter is now closed.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other cardio-renal-metabolic companies
- DexCom, Inc. DXCM
- Penumbra Inc PEN
- Insulet Corp PODD
- MiniMed Group, Inc. MMED
- Heartflow, Inc. HTFL
- iRhythm Holdings, Inc. IRTC
- Pulse Biosciences, Inc. PLSE
- AtriCure, Inc. ATRC
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.